Osteosarcoma (OS) is the most common primary malignant bone tumor. Despite advances in neoadjuvant multi-agent chemotherapy, the outcome of patients has not significantly improved in the last decades, making the search for more effective therapeutic agents imperative. In the present study, we explored the possibility of using activator protein-1 inhibition by 3-[(dodecylthiocarbonyl)methyl]-glutarimide (DTCM-g) as a new therapeutic strategy in two OS cell lines, HOS and MG-63. Our results showed that low concentrations (2.5, 5, 10, and 20 μg/mL) of the drug significantly decreased cell proliferation and clonogenic capacity, albeit it did not significantly induce cell death. DTCM-g also decreased cell invasiveness, and inhibited PDPN, MMP-2, TIMP1, and TIMP2 expressions. Moreover, our results showed that DTCM-g synergized with ionizing radiation in both cell lines while chemosensitized MG-63 cells to doxorubicin treatment. Even though additional laboratorial and preclinical tests are still needed to support our data, we demonstrate that DTCM-g inhibits growth in OS cells, increases the cytotoxicity of other commonly used agents, and may possess antimetastatic activity.
Get full access to this article
View all access options for this article.
References
1.
RaymondAK, AyalaAG, KnuutilaS. Conventional osteosarcoma. FletcherCDM, UnniKK, MertensF. Pathology and Genetics of Tumours of Soft Tissue and Bone.World Health Organization Classification of Tumours. Lyon: IARC Press, 2002; 264.
2.
ChouAJ, GellerDS, GorlickR. Therapy for osteosarcoma: Where do we go from here?Paediatr Drugs, 2008; 10:315.
3.
DaiX, MaW, HeXet al.Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit, 2001; 17:RA177.
4.
BielackSS, Kempf-BielackB, DellingGet al.Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 2002; 20:776.
5.
GoorinAM, SchwartzentruberDJ, DevidasMet al.Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol, 2003; 21:1574.
6.
JaffeN. Osteosarcoma: Review of the past, impact on the future. The American experience. Cancer Treat Res, 2009; 152:239.
7.
HessJ, AngelP, Schorpp-KistnerM. AP-1 subunits: Quarrel and harmony among siblings. J Cell Sci, 2004; 117,Pt 25:5965.
8.
PapachristouDJ, BatistatouA, SykiotisGPet al.Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. Bone, 2003; 32:364.
9.
LeanerVD, ChickJF, DonningerHet al.Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma. Am J Pathol, 2009; 174:265.
10.
WangZ, IgarashiM, IkedaYet al.Inhibition of NF kappa B activation by 9-methylstreptimidone isolated from Streptomyces. Heterocycles, 2006; 69:377.
11.
TakeiriM, TachibanaM, KanedaAet al.Inhibition of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone. Inflamm Res, 2011; 60:879.
12.
IshikawaY, TachibanaM, MatsuiCet al.Synthesis and biological evaluation on novel analogs of 9-methylstreptimidone, an inhibitor of NF-kappaB. Bioorg Med Chem Lett, 2009; 19:1726.
13.
FrankenNA, RodermondHM, StapJet al.Clonogenic assay of cells in vitro. Nat Protoc, 2006; 1:2315.
14.
LeeYJ, ShacterE. Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem, 1999; 274:19792.
15.
LiangCC, ParkAY, GuanJL. In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc, 2007; 2:329.
16.
ScrideliCA, CarlottiCGJr., OkamotoOKet al.Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: Identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol, 2008; 88:281.
17.
ScrideliCA, CortezMA, YunesJAet al.mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: Potential role of TIMP1 as an adverse prognostic factor. Leuk Res, 2010; 34:32.
18.
LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) Method. Methods, 2001; 25:402.
19.
TaoY, ZhangP, FrascognaVet al.Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer, 2007; 97:1664.
20.
ChouTC, TalalayP. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 1984; 22:27.
21.
van RiggelenJ, BuchwalterG, SotoUet al.Loss of net as repressor leads to constitutive increased c-fos transcription in cervical cancer cells. J Biol Chem, 2005; 280:3286.
22.
SanchoR, NateriAS, de VinuesaAGet al.JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J, 2009; 28:1843.
23.
ZhouY, YauC, GrayJWet al.Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer, 2007; 7:59.
24.
MathasS, HinzM, AnagnostopoulosIet al.Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J, 2002; 21:4104.
25.
ShenQ, UrayIP, LiYet al.The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene, 2008; 27:366.
26.
SugiokaY, WatanabeT, InagakiYet al.c-Jun NH2-terminal kinase pathway is involved in constitutive matrix metalloproteinase-1 expression in a hepatocellular carcinoma-derived cell line. Int J Cancer, 2004; 109:867.
27.
JorgensenK, DavidsonB, FlorenesVA. Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma. Mod Pathol, 2006; 19:1446.
28.
BaekMK, KimMH, JangHJet al.EGF stimulates uPAR expression and cell invasiveness through ERK, AP-1, and NF-kappaB signaling in human gastric carcinoma cells. Oncol Rep, 2008; 20:1569.
29.
GrigoriadisAE, SchellanderK, WangZQet al.Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol, 1993; 122:685.
30.
WangZQ, LiangJ, SchellanderKet al.c-fos-induced osteosarcoma formation in transgenic mice: Cooperativity with c-jun and the role of endogenous c-fos. Cancer Res, 1995; 55:6244.
31.
DassCR, KhachigianLM, ChoongPF. c-Jun is critical for the progression of osteosarcoma: Proof in an orthotopic spontaneously metastasizing model. Mol Cancer Res, 2008; 6:1289.
32.
PalankiMS. Inhibitors of AP-1 and NF-kappa B mediated transcriptional activation: Therapeutic potential in autoimmune diseases and structural diversity. Curr Med Chem, 2002; 9:219.
33.
TakadaY, SethiG, SungBet al.Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells. Mol Pharmacol, 2008; 73:1549.
34.
UchihashiS, FukumotoH, OnodaMet al.Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyl transferase isoforms. Drug Metab Dispos, 2011; 39:803.
35.
DhandapaniKM, MaheshVB, BrannDW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem, 2007; 102:522.
36.
HsiehYS, ChuSC, YangSFet al.Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis, 2007; 28:977.
37.
KwonHK, HwangJS, SoJSet al.Cinnamon extract induces tumor cell death through inhibition of NFkappaB and AP1. BMC Cancer, 2011; 10:392.
BriccoliA, RoccaM, SaloneMet al.High grade osteosarcoma of the extremities metastatic to the lung: Long-term results in 323 patients treated combining surgery and chemotherapy, 1985–2005. Surg Oncol, 2009; 19:193.
40.
ChakrabortiS, MandalM, DasSet al.Regulation of matrix metalloproteinases: An overview. Mol Cell Biochem, 2003; 253:269.
41.
OzanneBW, SpenceHJ, McGarryLCet al.Transcription factors control invasion: AP-1 the first among equals. Oncogene, 2007; 26:1.
42.
KunitaA, KashimaTG, OhazamaAet al.Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol, 2011; 179:1041.
43.
DassCR, KhachigianLM, ChoongPF. c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol Cancer Ther, 2008; 7:1909.
44.
TanML, ChoongPF, DassCR. Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours. Cancer Cell Int, 2001; 10:9.
45.
PotapovaO, HaghighiA, BostFet al.The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem, 1997; 272:14041.
46.
PotapovaO, GorospeM, DoughertyRHet al.Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol, 2000; 20:1713.
47.
PotapovaO, GorospeM, BostFet al.c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J Biol Chem, 2000; 275:24767.
48.
PotapovaO, BasuS, MercolaDet al.Protective role for c-Jun in the cellular response to DNA damage. J Biol Chem, 2001; 276:28546.
49.
JohnstonSR, LuB, ScottGKet al.Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res, 1999; 5:251.
50.
SmithLM, WiseSC, HendricksDTet al.cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene, 1999; 18:6063.
51.
BaileyS, HallAG, PearsonADet al.The role of AP-1 in glucocorticoid resistance in leukaemia. Leukemia, 2001; 15:391.
52.
BorchielliniD, Etienne-GrimaldiMC, ThariatJet al.The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes. Cancer Treat Rev, 2012; 38:737.
53.
OzakiT, FlegeS, KevricMet al.Osteosarcoma of the pelvis: Experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol, 2003; 21:334.
54.
OertelS, BlattmannC, RiekenSet al.Radiotherapy in the treatment of primary osteosarcoma -a single center experience. Tumori, 2010; 96:582.
55.
KajanneR, MiettinenP, TenhunenMet al.Transcription factor AP-1 promotes growth and radio resistance in prostate cancer cells. Int J Oncol, 2009; 235:1175.
